Billy Cordon, MD
Urology · New York, NYNPI 1447494901
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.4%), food and beverage and education — rather than concentrated in one kind of arrangement. Coloplast accounts for 65.6% of it on its own, with 45 other manufacturers making up the rest. 2025 is the largest year on record at $37,989, 2.9 times the $12,959 reported in 2019. Among urology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 365 payments — averaging $217.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$52K
- Endo USA, Inc.$16K
- Boston Scientific$3K
- Biotissue Holdings Inc.$2K
- Teleflex LLC$1K
- Endo Pharmaceuticals Inc.$905
- plus $4K from 40 others
Across 4 payments — averaging $1450.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Endo USA, Inc.$6K
What the payments were for
- Consulting fees$35,17844%
- Travel & lodging$11,95815%
- Food & beverage$16,63921%
- Education$15,49720%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TITAN$50,025
- XIAFLEX$15,688
- CLARIX$1,141
- NEOX$1,007
- UroLift$656
- AMS 700$610
- REZUM$458
- UroLift System$322
- GENERAL ERECTILE DYSFUNCTION$295
- AVEED$265
- AMS$252
- eCoin Device Kit$169
- TOROSA$163
- ADSTILADRIN$162
- SpaceOAR VUE System - 10mL$158
- Barrigel$157
- TRINITY$154
- SWISS LITHOCLAST TRILOGY$152
- GENERAL KIDNEY STONE DISEASE$150
- AMS 700 CXR RTE KIT$139
How this compares
$79,272 in reported general payments places this provider in the 95th percentile of 952 urology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiaflexCollagenase Clostridium Hist. | 20 | $266,333 |
| GemtesaVibegron | 125 | $80,859 |
| MyrbetriqMirabegron | 28 | $22,531 |
| Tadalafil | 38 | $6,393 |
| Methenamine Hippurate | 26 | $2,276 |
| Potassium Citrate ErPotassium Citrate | 17 | $1,845 |
| Testosterone Cypionate | 30 | $1,570 |
| Tamsulosin Hcl | 162 | $1,524 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 26 | $525 |
| Ciprofloxacin Hcl | 66 | $373 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 65 | $323 |
| Oxybutynin Chloride ErOxybutynin Chloride | 27 | $299 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 60 | $271 |
| Fluconazole | 36 | $237 |
| Cefdinir | 23 | $224 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Endo Pharmaceuticals Inc.Xiaflex | $905 | $266,33320 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $75 | $80,859125 claims |
| Astellas Pharma US IncMyrbetriq | $445 | $22,53128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 952 urology providers in New York.
Other urology in New York
- Bilal ChughtaiNew York$658K
- Katie MurrayNew York$575K
- Neil BanderNew York$544K
- Robert ValenzuelaNew York$494K
- Kyrollis AttallaNew York$381K
- Benjamin BruckerNew York$364K
- Ketan BadaniNew York$285K
- Michael GrassoNew York$284K
- Mantu GuptaNew York$229K
- Robin SmithNew York$215K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.